远端缺血适应联合依达拉奉右莰醇治疗急性脑梗死患者的效果

doi:10.3760/cma.j.cn441417-20240827-10012

摘要/Abstract

摘要：

目的　探讨远端缺血适应（RIC）联合依达拉奉右莰醇治疗急性脑梗死患者的效果。方法　采用前瞻性、随机对照研究，选取2021年7月至2023年7月西安医学院第三附属医院收治的160例急性脑梗死患者为研究对象，随机数字表法分为对照组（接受依达拉奉右莰醇治疗）和研究组（在对照组基础上接受RIC治疗），均治疗12周。对照组80例，男41例、女39例，年龄（63.37±7.48）岁；研究组80例，男46例、女34例，年龄（62.59±6.97）岁。比较两组患者总有效率及不良反应发生率，比较两组患者治疗前与治疗2、4、12周时的促炎因子［肿瘤坏死因子α（TNF-α）、白细胞介素1β（IL-1β）、白细胞介素6IL-6）］、s100钙结合蛋白（S100B）、神经功能［采用修订Rankin量表（MRS）评分、美国国立卫生研究院卒中量表（NIHSS）评分］、神经保护因子［血管内皮生长因子（VEGF）、脑源性神经营养因子（BDNF）］水平。采用t检验、χ2检验进行统计分析。结果　研究组患者总有效率92.50%（74/80），高于对照组的80.00%（64/80），两组比较差异有统计学意义（P<0.05）。研究组患者不良反应发生率12.50%（10/80），对照组为10.00%（8/80），两组比较差异无统计学意义（P>0.05）。治疗后两组患者TNF-α、IL-1β、IL-6、S100B水平及MRS、NIHSS评分均低于治疗前，且研究组低于对照组（均P<0.05）；治疗后两组患者VEGF、BDNF水平高于治疗前，且研究组高于对照组（均P<0.05）。结论　RIC联合依达拉奉右莰醇治疗急性脑梗死疗效显著，可改善患者的神经功能，提高整体预后

关键词: 急性脑梗死； , , 远端缺血适应； , , 依达拉奉右莰醇； , , 神经功能； , , 促炎因子

Abstract:

Objective　To explore the effect of remote ischemic conditioning (RIC) combined with edaravone and dexamethasone for patients with acute cerebral infarction. Methods　One hundred and sixty patients with acute cerebral infarction treated at The Third Affiliated Hospital of Xi'an Medical University between July 2021 and July 2023 were selected for the randomized controlled trial. The patients were divided into a control group and a study group by the random number table method, with 80 cases in each group. There were 41 males and 39 females in the control group; they were (63.37±7.48) years old. There were 46 males and 34 females in the study group; they were (62.59±6.97) years old. The control group were treated with edaravone and dexamethasone; in addition, the study group were treated with RIC. The total effective rates, incidence rates of adverse reactions, and levels of pro-inflammatory factors [tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), and interleukin 6 (IL-6)], levels of S100 calcium-binding protein B (S100B), neurological function [scores of the Modified Rankin Scale (MRS) and the National Institutes of Health Stroke Scale (NIHSS)], and levels of neuroprotective factors [vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF)] before and 2, 4, 12 weeks after the treatment were compared between the two groups. t and χ² tests were used for the statistical analysis. Results　There was a statistical difference in the total effective rate between the study group and the control group [92.50% (74/80) vs. 80.00% (64/80); P<0.05]. There was no statistical difference in the total effective rate between the study group and the control group [12.50% (10/80) and 10.00% (8/80); P>0.05]. After the treatment, the levels of TNF-α, IL-1β, S100B, and IL-6 were lower than those before the treatment in both groups, and the levels in the study group were lower than those in the control group (all P<0.05). After the treatment, the levels of VEGF and BDNF were higher than those before the treatment in both groups, and the levels in the study group were higher than those in the control group (all P<0.05). Conclusion　RIC combined with edaravone and dexamethasone for patients with acute cerebral infarction is effective, and can improve their neurological function and prognosis.

Key words: Acute cerebral infarction, Remote ischemic conditioning, Edaravone and dexamethasone, Neurological function, Inflammatory markers

周美宁张玲如. 远端缺血适应联合依达拉奉右莰醇治疗急性脑梗死患者的效果 [J]. 国际医药卫生导报, 2025, 31(10): 1641-1645.

Zhou Meining, Zhang Lingru.

Remote ischemic conditioning combined with edaravone and dexamethasone for patients with acute cerebral infarction [J]. International Medicine and Health Guidance News, 2025, 31(10): 1641-1645.

参考文献

[1]张建村,王新星,仝海波.血小板活化在急性脑梗死中的作用研究进展[J].中国卒中杂志,2024,19(5):579-585. DOI:10.3969/j.issn.1673-5765.2024.05.014.

[2]邵枝定,许忠强,许利.丁苯酞联合阿司匹林、阿加曲班治疗急性脑梗死的疗效[J].中国老年学杂志,2023,43(3):523-526. DOI:10.3969/j.issn.1005-9202.2023.03.004.

[3]马炎奇,靳珍怡,温喜喜,等.急性脑梗死3.0T MR ARMS DWI与常规MS-EPI DWI图像质量对照研究[J].中国医学计算机成像杂志,2023,29(3):231-235. DOI:10.3969/j.issn.1006-5741.2023.03.002.

[4]胡美云,王月波.头颅MRI、DWI和SWI在急性脑梗死出血性转化诊断中的应用[J].郑州大学学报(医学版),2023,58(4):581-584. DOI:10.13705/j.issn.1671-6825. 2022.08.064.

[5]杨利,何晓宏,王小慧,等.不同针灸介入时机对大脑中动脉供血区急性脑梗死神经功能预后的影响[J].中华中医药学刊,2024,42(5):196-200. DOI:10.13193/j.issn.1673- 7717.2024.05.040.

[6]国家卫生健康委员会急诊医学质控中心,中国医师协会急诊医师分会,世界中医药学会联合会急症专业委员会.中国急性缺血性脑卒中急诊诊治专家共识[J].中国急救医学,2018,38(4):281-287. DOI:10.3969/jz.issn.1002-1949. 2018.04.001.

[7]陈安琪,常英娟,吕秀花,等.成人胼胝体细胞毒性病变与胼胝体压部急性脑梗死的临床及MRI鉴别[J].临床放射学杂志,2023,42(8):1220-1226.DOI:10.13437/j.cnki.jcr. 2023.08.011.

[8]蒋柳阳,许文萱,侯筱宇.缺血后适应在急性低氧缺血性脑病中的保护机制及药物靶标发现[J].生理科学进展,2023,54(3):228-234. DOI:10.3969/j.issn.0559-7765. 2023.03.011.

[9]张翠翠,耿娜,孙效影.远端缺血预适应对老年急性心肌梗死患者介入治疗术后对比剂肾病的预防[J].医学影像学杂志,2022,32(12):2190-2193.

[10]张盼盼,王菊霞,赵勇,等.远端缺血后适应联合早期康复护理对急性缺血性脑卒中的康复效果研究[J].蚌埠医学院学报,2022,47(8):1102-1106. DOI:10.13898/j.cnki.issn.1000-2200.2022.08.026.

[11]孙璐璐,夏茹楠,袁强强,等.依达拉奉右莰醇合理性评价标准的建立及应用[J].河北医药,2024,46(10):1540-1543. DOI:10.3969/j.issn.1002-7386.2024.10.022.

[12]石岩硕,要凯青,曹格溪,等.依达拉奉右莰醇联合丁苯酞氯化钠治疗急性脑梗死的系统评价[J].中国医院用药评价与分析,2024,24(5):598-601,605. DOI:10.14009/j.issn. 1672-2124.2024.05.019.

[13]杜娟,周晓雨,张淼,等. Solitaire支架机械取栓结合双重抗血小板治疗对急性脑梗死患者肢体功能和血管再闭塞的影响[J].实用医学杂志,2024,40(14):1952-1956. DOI:10.3969/j.issn.1006-5725.2024.14.009.

[14]陈正文,李沛城,刘一之,等.静脉溶栓桥接血管内治疗术中使用替罗非班治疗急性前循环大血管闭塞性脑梗死的安全性研究[J].中华神经医学杂志,2023,22(2):149-156. DOI:10.3760/cma.j.cn115354-20221111-00826.

[15]闵敬亮,郭亚玲,周星辰,等.动脉内替罗非班治疗在急性前循环脑梗死机械取栓术中的临床研究[J].中国临床药理学杂志,2024,40(10):1395-1399. DOI:10.13699/j.cnki. 1001-6821.2024.10.001.

[16]刘前,邓倩,周静,等.依达拉奉右莰醇联合阿托伐他汀治疗老年急性脑梗死的临床疗效及对脑血流动力学的影响[J].中国老年学杂志,2023,43(2):276-279. DOI:10.3969/j.issn.1005-9202.2022.02.006.

[17]佟亚男,孙鲁生,陈锦荣,等.基于多准则决策的达格列净联合奥拉西坦治疗2型糖尿病合并急性脑梗死患者效益与风险评价[J].中国糖尿病杂志,2023,31(5):340-345. DOI:10.3969/j.issn.1006-6187.2023.05.005.

[18]于佳浩,甄瑾,韩雪,等.头颅CT联合MRI-DWI对急性脑梗死的评估分析[J].医学影像学杂志,2024,34(9):5-8.

[19]肖健豪,李清华,陈丽华,等.提高急性脑梗死再灌注治疗率[J].中国卫生质量管理,2024,31(7):72-75. DOI:10.13912/j.cnki.chqm.2024.31.7.16.

[20]林骏荣,丁德权,黄静,等.通督醒神针刺法治疗急性脑梗死的疗效观察[J].中国中医急症,2024,33(10):1763-1766. DOI:10.3969/j.issn.1004-745X.2024.10.016.

[21]孙剑波,闫力永,马程. MRI-DWI联合PWI对急性脑梗死患者预后诊断价值[J].中国CT和MRI杂志,2024,22(5):4-6. DOI:10.3969/j.issn.1672-5131.2024.05.002.

[22]付胜奇,李浩然,朱利利,等.脑微出血对急性脑梗死患者血管再通治疗后的影响[J].中风与神经疾病杂志,2024,41(2):129-134. DOI:10.19845/j.cnki.zfysjjbzz.2024.0025.

[23]林雅明,吴云虹,肖林婷,等.依达拉奉右莰醇联合丁苯酞治疗急性脑梗死患者的临床研究[J].中国临床药理学杂志,2023,39(18):2602-2606. DOI:10.13699/j.cnki.1001- 6821.2023.18.004.

[24]俞梁,杨越,楼晶晶,等.银杏达莫注射液联合丁苯酞氯化钠注射液治疗急性脑梗死患者的临床研究[J].中国临床药理学杂志,2023,39(4):459-463. DOI:10.13699/j.cnki. 1001-6821.2023.04.001.

[25]崔二平,侯志刚,许伟,等.依达拉奉右莰醇联合替罗非班辅助综合康复干预治疗老年急性脑梗死的临床疗效[J].中国老年学杂志,2023,43(16):3858-3860. DOI:10.3969/j.issn.1005-9202.2023.16.006.